Showing results (161-170 of 167) with videos related to
Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 167 results.
Cell Reports. Medicine|December 28, 2024
Coupling of response biomarkers between tumor and peripheral blood in patients undergoing chemoimmunotherapyWee Loong Chin, Alistair M Cook, Jonathan Chee, et al.Lancet (London, England)|February 14, 2021
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trialMichael S Hofman, Louise Emmett, Shahneen Sandhu, et al.European Urology Oncology|February 3, 2026
Radiographic Progression Without Prostate-specific Antigen Progression in Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Analysis of the ENZAMET Trial (ANZUP 1304)Andrisha-Jade Inderjeeth, Andrew J Martin, Robert R Zielinski, et al.Radiology|April 28, 2026
177Lu-PSMA-617 SPECT/CT for Early Prediction of Overall Survival in Participants with Metastatic Castration-Resistant Prostate CancerNarjess Ayati, Nathan Papa, Megan Crumbaker, et al.The Lancet. Oncology|February 16, 2025
Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trialLouise Emmett, Shalini Subramaniam, Megan Crumbaker, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2021
Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUPMartin R Stockler, Andrew J Martin, Ian D Davis, et al.The Lancet. Oncology|April 15, 2024
[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trialLouise Emmett, Shalini Subramaniam, Megan Crumbaker, et al.Pageof 17